Prospects for control of herpes simplex virus disease through immunization

Clinical Infectious Diseases

Volumn 30, Issue 3, 2000, Pages 549-566

  Stanberry, Lawrence R ^a,f   Cunningham, Anthony L ^c   Mindel, Adrian ^g   Scott, Laurie L ^g   Spruance, Spotswood L ^b   Aoki, Fred Y ^d   Lacey, Charles J ^e  

^a UNIVERSITY OF CINCINNATI   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF MANITOBA   (Canada)

^e IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^f CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^g NONE

Author keywords

[No Author keywords available]

Indexed keywords

HERPES SIMPLEX VACCINE; INACTIVATED VACCINE; LIVE VACCINE;

GENITAL HERPES; HERPES SIMPLEX; HERPES SIMPLEX ENCEPHALITIS; HERPES SIMPLEX KERATITIS; HERPES SIMPLEX VIRUS; HUMAN; IMMUNIZATION; IMMUNOBIOLOGY; IMMUNOPATHOLOGY; INFECTION CONTROL; INFECTION PREVENTION; NEUROLOGICAL COMPLICATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

FEMALE; HERPES GENITALIS; HERPES SIMPLEX; HUMANS; MALE; SIMPLEXVIRUS; VACCINATION; VIRAL VACCINES;

EID: 0034034204     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/313687     Document Type: Review

References (198)

1. 1. Stanberry LR. Herpes simplex virus vaccines as immunotherapeutic agents. Trends Microbiol 1995; 3:244-7.
2. 2. McKenzie R, Straus SE. Therapeutic immunization for recurrent herpes simplex virus infections. In: Mills J, Volberding PA, Corey L, eds. Antiviral chemotherapy 4. New York: Plenum Press, 1996:67-83.
3. 3. Bernstein DI, Stanberry LR. Herpes simplex virus vaccines. Vaccine 1999; 17: 1681-9.
4. + T-cell clones recovered from recurrent genital herpes simplex virus type 2 lesions. J Virol 1994; 68:2803-10.
5. 5. Whitley RJ. Herpes simplex vaccines. In: Levine MM, Woodrow GC, Kaper JB, Cobon GS, eds. New generation vaccines. 2d ed. New York: Marcel Dekker, 1997:727-48.
6. 6. Stanberry LR. The pathogenesis of herpes simplex virus infections. In: Stanberry LR, ed. Genital and neonatal herpes. London: John Wiley & Sons, 1996:31-48.
7. 7. Stanberry LR, Kern ER, Richards JT, Abbott TM, Overall JC Jr. Genital herpes in guinea pigs: pathogenesis of the primary infection and the description of recurrent disease. J Infect Dis 1982; 146:397-404.
8. 8. Stanberry LR, Kit S, Myers MG. Thymidine kinase-deficient herpes simplex virus type 2 genital infection in guinea pigs. J Virol 1985; 55:322-8.
9. 9. Siegal FP, Lopez C, Hammer GS, et al. Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions. N Engl J Med 1981; 305:1439-44.
10. 10. Cunningham AL, Merigan TC. Interferon production appears to predict time of recurrence or herpes labialis. J Immunol 1983; 130:2397-9.
11. + cytotoxic T-lymphocyte precursors specific for herpes simplex viruses in persons with genital herpes. J Virol 1996; 70:8165-8.
12. 12. Whitley RJ, Kimberlin D, Roizman B. Herpes simplex viruses. Clin Infect Dis 1998; 26:541-53.
13. 13. Whitley RJ, Levin M, Barton N, et al. Infections caused by herpes simplex virus in the immunocompromised host: natural history and topical acyclovir therapy. J Infect Dis 1984; 150:323-9.
14. 14. Shillitoe EJ, Wilton JMA, Lehner T. Sequential changes in cell-mediated immune responses to herpes simplex vims after recurrent herpetic infection in humans. Infect Immun 1977; 18:130-7.
15. 15. O'Reilly RJ, Chibbaro A, Anger E, Lopez C. Cell-mediated immune responses in patients with recurrent herpes simplex infections. J Immunol 1977; 118:1095-102.
16. 16. Green JA, Weiss PN, Yeh TJ, Spmance SL. Immune specific interferon production by peripheral blood mononuclear leukocytes from patients with primary and recurrent oral-labial herpes simplex virus infections. J Med Virol 1985; 16:297-305.
17. 17. Sheridan JF, Beck B, Smith CC, Aurelian L. Reactivation of herpes simplex virus is associated with production of a low molecular weight factor that inhibits lymphokine activity in vitro. J Immunol 1987; 138:1234-9.
18. 18. Kuo Y, Lin C. Recurrent herpes simplex virus type 1 infection precipitated by the impaired production of interleukin-2, α-interferon, and cell-mediated immunity. J Med Virol 1990; 31:183-9.
19. 19. Green JA, Yeh TJ, Overall JC. Sequential production of IFN-α and immune-specific IFN-γ by human mononuclear leukocytes exposed to herpes simplex virus. J Immunol 1981; 127:1192-6.
20. 20. Torseth JW, Merigan TC. Significance of local gamma interferon in recurrent herpes simplex infection. J Infect Dis 1986; 153:979-84.
21. 21. Spruance SL, Evans TG, McKeough MB, et al. Th1/Th2-like immunity and resistance to herpes simplex labialis. Antiviral Res 1995; 28:39-55.
22. 22. Mikloska Z, Kesson AM, Penfold ME, Cunningham AL. Herpes simplex virus protein targets for CD4 and CD8 lymphocyte cytotoxicity in cultured epidermal keratinocytes treated with interferon-γ. J Infect Dis 1996; 173:7-17.
23. 23. Cunningham AL, Merigan TC. Leu3 T cells produce gamma-interferon in patients with recurrent herpes labialis. J Immunol 1984; 132:197-202.
24. 24. Mikloska Z, Danis VA, Adams S, Lloyd AR, Adian DL, Cunningham AL. In vivo production of cytokines and β [C-C] chemokines in human recurrent herpes simplex lesions - do herpes simplex virus infected keratinocytes contribute to their production? J Infect Dis 1998; 177:827-38.
25. 25. Koelle DM, Tigges MA, Burke RL, et al. Herpes simplex virus infection of human fibroblasts and keratinocytes inhibits recognition by cloned CDS cytotoxic T lymphocytes. J Clin Invest 1993; 91:961.
26. 26. Cunningham AL, Noble JR. Role of keratinocytes in human recurrent herpetic lesions. Ability to present herpes simplex antigen and act as targets for T lymphocyte cytotoxicity in vitro. J Clin Invest 1989; 83:490-6.
27. 27. Koelle DM, Posavad CM, Barnum GR, Johnson ML, Frank JM, Corey L. Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes. J Clin Invest 1998; 101:1500-8.
28. 28. Mikloska Z, Cunningham AL. Herpes simplex virus type 1 glycoproteins gB, gC, and gD are major targets for CD4 lymphocyte cytotoxicity in HLA-DR expressing human epidermal keratinocytes. J Gen Virol 1998; 79:353-61.
29. 29. Koelle DM, Frank JM, Johnson ML, Kwok WW. Recognition of herpes simplex virus type 2 tegument proteins by CD4 T cells infiltrating human genital herpes lesions. J Virol 1998; 72:74-6.
30. 30. Bernstein DI, Stanberry LR, Harrison CJ, Kappes J, Myers MG. Effects of oral acyclovir treatment of initial genital HSV-2 infection upon antibody response, recurrence patterns and subsequent HSV-2 reinfection in guinea pigs. J Gen Virol 1986; 67:1601-12.
31. 31. Bernstein DI, Harrison CJ, Jenski L, Myers MG, Stanberry LR. Cell-mediated immunological responses and recurrent genital herpes in the guinea pig: effects of glycoprotein immunotherapy. J Immunol 1991; 146: 3571-7.
32. 32. Milligan GN, Berstein DI. Generation of humoral immune responses against herpes simplex virus type 2 in the murine female genital tract. Virology 1995; 206:234-41.
33. 33. Milligan GN, Bernstein DI. Analysis of herpes simplex virus-specific T cells in the murine female genital tract following genital infection with herpes simplex virus type 2. Virology 1995; 212:481-9.
34. 34. McDermott MR, Goldsmith CH, Rosenthal KS, Brais LJ. T lymphocytes in the genital lymph nodes protect mice from intravaginal infection with herpes simplex virus type 2. J Infect Dis 1989; 159:460-6.
35. 35. Stanberry LR, Bernstein DI, Kit S, Myers MG. Genital reinfection after recovery from initial herpes simplex virus type 2 genital infection in guinea pigs. J Infect Dis 1986; 153:1055-61.
36. 36. Milligan GN, Bernstein DI, Bourne N. T lymphocytes are required for protection of the vaginal mucosae and sensory ganglia of immune mice against reinfection with herpes simplex virus type 2. J Immunol 1998; 160:6093-100.
37. 37. Bourne N, Stanberry LR. Modification of primary and recurrent genital herpes in guinea pigs by passive immunoprophylaxis [abstract 156]. Antiviral Res 1993; 20(Suppl 1):127.
38. 38. Hall RL, MacKneson RG, Ormsby HL. Studies of immunity in experimental herpetic keratitis in rabbits. Am J Ophthalmol 1955; 39:226-33.
39. 39. Okumoto M, Jawetz E, Sonne M. Studies on herpes simplex virus. Am J Ophthalmol 1959; 47:61-6.
40. 40. Ey RC, Hughes WF, Holmes AW, Deinhardt F. The effect of IDU on experimental and clinical herpes simplex infections. Trans Am Ophthalmol Soc 1963; 61:100-7.
41. 41. Carter C, Easty DL. Experimental ulcerative keratitis. L Systemic immune responses and resistance to corneal infection. Br J Ophthalmol 1981; 65: 77-81.
42. 42. Easty DL. Virus diseases of the eye. Chicago: Year Book Medical Publishers, 1985:104-5.
43. 43. Rouse BT, Atherton SS. Immunopathology of herpesvirus infections. In: Medveczky PG, Friedman H, Bendinelli M, eds. Herpesvirus and immunity. New York: Plenum Press, 1998:33-51.
44. 44. Niemialtowski MG, Rouse BT. Predominance of Th1 cells in ocular tissues during herpetic stromal keratitis. J Immunol 1992; 149:3035-9.
45. 45. Hendricks RL, Tumpey TM, Finnegan A. IFN-γ and IL-2 are protective in the skin but pathologic in the corneas of HSV-1-infected mice. J Immunol 1992; 149:3023-8.
46. 46. Kanangat S, Thomas J, Gangappa S, Babu JS, Rouse BT. HSV-1-mediated upregulalion of IL-12 occurs in response to HSV infection in the mouse eye. J Immunol 1996; 156:1110-6.
47. 47. Koutsky LA, Stevens CE, Holmes KK, et al. Underdiagnosis of genital herpes by current clinical and viral-isolation procedures. N Engl J Med 1992; 326:1533-9.
48. 48. Skoldenberg B, Jeansson S, Wolontis S. Herpes simplex virus type 2 and acute aseptic meningitis: atypical features of cases with isolation of herpes simplex virus from cerebrospinal fluids. Scand J Infect Dis 1975; 7: 227-32.
49. 49. Goodell SE. Quinn TC, Mirtichian E, Schuffler MD, Holmes KK, Corey L. Herpes simplex virus proctitis in homosexual men. N Engl J Med 1983; 308:868-71.
50. 50. Carney O, Ross E, Bunker C, Ikkos G, Mindel A. A prospective study of the psychological impact on patients with a first episode of genital herpes. Genitourin Med 1994; 70:40-5.
51. 51. Cameron DW, Simonsen JN, D'Costa LJ, et al. Female to male transmission of human immunodeficiency virus type 1: risk factors for seroconversion in men. Lancet 1989; 2:403-7.
52. 52. Lafferty WE, Coombs RW, Benedetti J, Critchlow C, Corey L. Recurrences after oral and genital herpes simplex virus infection: influence of anatomic site and viral type. N Engl J Med 1987; 316:1444-9.
53. 53. Wald A, Corey L, Cone R, Hobson A, Davis G, Zeh J. Frequent genital herpes simplex virus 2 shedding in immunocompetent women: effect of acyclovir treatment. J Clin Invest 1997; 99:1092-7.
54. 54. Wald A, Zeh J, Selke S, Ashley RL, Corey L. Virologic characteristics of subclinical and symptomatic genital herpes infection. N Engl J Med 1995; 333:770-5.
55. 55. Schacker T, Hu HL, Koelle DM, et al. Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HTV-infected persons: a double-blind, placebo-controlled trial. Ann Intern Med 1998; 128:21-8.
56. 56. Strand A, Vahlne A, Svennerholm B, et al. Asymptomatic virus shedding in men with genital herpes infection. Scand J Infect Dis 1986; 18:195-7.
57. 57. Mertz GJ, Benedetti J, Ashley R, et al. Risk factors for the sexual transmission of genital herpes. Ann Intern Med 1992; 116:197-202.
58. 58. Johnson RE, Nahmias AJ, Magder LS, et al. A seroepidemiologic survey for the prevalence of herpes simplex virus type 2 infection in the United States. N Engl J Med 1989; 321:7-12.
59. 59. Fleming DT, McQuillan GM, Johnson RE, et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med 1997; 337:1105-11.
60. 60. Breinig MK, Kingsley LA, Armstrong JA, Freeman DJ, Ho M. Epidemiology of genital herpes in Pittsburgh: serologic, sexual, and racial correlates of apparent and inapparent herpes simplex infections. J Infect Dis 1990; 162:299-305.
61. 61. Gibson JJ, Hornung CA, Alexander GR, Lee FK, Potts WA, Nahmias AJ. A cross-sectional study of herpes simplex virus types 1 and 2 in college students. J Infect Dis 1990; 162:306-12.
62. 62. Cowan FM, Johnson AM, Ashley R, Corey L, Mindel A. Antibody to herpes simplex virus type 2 as serological marker of sexual lifestyle in populations. BMJ 1994; 309:1325-9.
63. 63. Eberhart-Phillips J, Dickson NP, Paul C, et al. Herpes simplex type 2 infection in a cohort aged 21 years. Sex Transm Infect 1998; 74:216-8.
64. 64. Rosenthal SL, Stanberry LR, Biro FM, et al. Seroprevalence of herpes simplex virus type 1 and type 2 and cytomegalovirus in adolescents. Clin Infect Dis 1997; 24:135-9.
65. 65. Nahmias AJ, Lee FK, Beckman-Nahmias S. Sero-epidemiological and -sociological patterns of herpes simplex virus infection in the world. Scand J Infect Dis Suppl 1990; 69:19-36.
66. 66. Spruance SL, Overall JC Jr, Kern ER, Krueger GG, Pliam V, Miller W. The natural history of recurrent herpes simplex labialis: implications of antiviral therapy. N Engl J Med 1977; 297:69-75.
67. 67. Bader C, Crumpacker CS, Schnipper LE, et al. The natural history of recurrent facial-oral infection with herpes simplex virus. J Infect Dis 1978; 138:897-905.
68. 68. Corey L, Adams HG, Brown ZA, Holmes KK. Genital herpes simplex virus infections: clinical manifestations, course, and complications. Ann Intern Med 1983; 98:958-72.
69. 69. Centifanto-Fitzgerald YM, Yamaguchi T, Kaufman HE, Tognon M, Roizman B. Ocular disease pattern induced by herpes simplex virus is genetically determined by a specific region of viral DNA. J Exp Med 1982; 155:475-89.
70. 70. Glezen WP, Fernald GW, Lohr JA. Acute respiratory disease of university students with special reference to the etiologic role of Herpesvirus hominis. Am J Epidemiol 1975; 101:111-21.
71. 71. Ship H, Morris AL, Durocher RT, Burket LW. Recurrent aphthous ulcerations and recurrent herpes labialis in a professional school student population. Oral Surg Oral Med Oral Pathol 1960; 13:1191-202.
72. 72. Embil JA, Stephens RG, Manuel FR. Prevalence of recurrent herpes labialis and aphthous ulcers among young adults on six continents. Can Med Assoc J 1975; 113:627-30.
73. 73. Grout P, Barber VE. Cold sores - an epidemiologic survey. J R Coll Gen Pract 1976; 26:428-34.
74. 74. Young SK, Rowe NH, Buchanan RA. A clinical study for the control of facial mucocutaneous herpes virus infections. I. Characterization of natural history in a professional school population. Oral Surg Oral Med Oral Pathol 1976; 41:498-507.
75. 75. Ship II, Miller MF, Ram C. A retrospective study of recurrent herpes labialis in a professional population, 1958-1971. Oral Surg Oral Med Oral Pathol 1977; 44:723-30.
76. 76. Douglas RG, Couch RB. A prospective study of chronic herpes simplex virus infection and recurrent herpes labialis in humans. J Immunol 1970; 104:289-95.
77. 77. Kaufman HE, Brown DC, Ellison EM. Recurrent herpes in the rabbit and man. Science 1967; 156:1628-9.
78. 78. Ramsey PG, Fife KH, Hackman RC, Meyers JD, Corey L. Herpes simplex virus pneumonia. Ann Intern Med 1982; 97:813-20.
79. 79. Spruance SL. Prophylactic chemotherapy with acyclovir for recurrent herpes simplex labialis. J Med Virol 1993; 1(Suppl 1):27-32.
80. 80. Tatnall FM, Schofield JK, Leigh IM. Double-blind placebo-controlled trial of continuous acyclovir in recurrent erythema multiforme. Br J Dermatol 1995; 132:267-70.
81. 81. Mindel A. Cutaneous herpes simplex infection. Scand J Infect Dis Suppl 1991; 80:47-52.
82. 82. Whitley RJ, Lakeman F. Herpes simplex virus infections of the central nervous system: therapeutic and diagnostic considerations. Clin Infect Dis 1995; 20:414-20.
83. 83. Reeves WC, Corey L, Adams HG, Vontver LA, Holmes KK. Risk of recurrence after first episodes of genital herpes. N Engl J Med 1981; 305: 315-9.
84. 84. Berry JA, Crowley T, Horner PJ, Harvey I. Orogenital sex as a risk factor for the development of primary genital herpes: a case-control study [abstract P487]. In: Abstracts of the International Congress of Sexually Transmitted Diseases (Seville. Spain), 1997:143.
85. 85. Stanberry LR, Jorgensen DM, Nahmias AJ. Herpes simplex viruses 1 and 2. In: Evans AS, Kaslow RA, eds. Viral infection of humans: epidemiology and control. 4th ed. New York: Plenum Press, 1997:419-54.
86. 86. Schomogyi M, Wald A, Corey L. Herpes simplex virus-2 infection: an emerging disease? Infect Dis Clin North Am 1998; 12:47-61.
87. 87. Kroon S, Whitley R, eds. Management strategies in herpes: can we improve management of perinatal herpes simplex virus infections? Worthing, UK: PPS Europe, 1995.
88. 88. Tookey P, Peckham CS. Neonatal herpes simplex virus infection in the British Isles. Paediatr Perinat Epidemiol 1996; 10:432-42.
89. 89. Maccato M. Herpes in pregnancy. Clin Obstet Gynecol 1993; 36:869-77.
90. 90. Florman AL, Gershon AA, Blackett PR, Nahmias AJ. Intrauterine infection with herpes simplex virus: resultant congenital malformations. JAMA 1973; 225:129-32.
91. 91. Stone KM, Brooks CA, Guinan ME, Alexander ER. National surveillance for neonatal herpes simplex virus infections. Sex Transm Dis 1989; 16: 152-6.
92. 92. Whitley RJ, Arvin AM, Prober CG, et al. Predictor of morbidity and mortality in neonates with herpes simplex virus infections. N Engl J Med 1991; 324:450-4.
93. 93. Arvin AM. The epidemiology of perinatal herpes simplex virus infections. In: Stanberry LR, ed. Genital and neonatal herpes. Chichester, England: John Wiley & Sons, 1996:179-92.
94. 94. Whitley RJ, Arvin AM. Herpes simplex virus infections. In: Remington JS, Klein JO, eds. Infectious diseases of the fetus and newborn infant. Philadelphia: WB Saunders, 1995:354-76.
95. 95. Douglas J, Schmidt O, Corey L. Acquisition of neonatal herpes from a paternal source contact. J Pediatr 1983; 103:908-10.
96. 96. Nahmias AJ, Visitine AM. Herpes simplex. In: Remington JS, Klein JO, eds. Infectious diseases of the fetus and newborn infant, Philadelphia: WB Saunders, 1976:156-90.
97. 97. Prober CG, Corey L, Brown ZA, et al. The management of pregnancies complicated by genital infections with herpes simplex virus. Clin Infect Dis 1992; 15:1031-8.
98. 98. Benedetti J, Corey L, Ashley R. Recurrence rates in genital herpes after symptomatic first-episode infection. Ann Intern Med 1994; 121:847-54.
99. 99. Brown ZA, Selke S, Zeh J, et al. The acquisition of herpes simplex during pregnancy. N Engl J Med 1997; 337:509-15.
100. 100. Nahmias AJ, Josey WE, Naib ZM, Freeman MG, Fernandez RJ, Wheeler JH. Perinatal risk associated with maternal genital herpes simplex virus infection. Am J Obstet Gynecol 1971; 110:825-37.
101. 101. Sweet RL, Gibbs RS. Herpes virus infection. In: Infectious diseases of the female genital tract. 2d ed. Baltimore: Williams & Wilkins, 1990.
102. 102. Yeager AS, Arvin AM, Urbani LJ, Kemp JA III. The relationship of antibody to outcome in neonatal herpes simplex virus infections. Infect Immun 1980; 29:532-8.
103. 103. Whitley RJ, Corey L, Arvin A, et al. Changing presentation of herpes simplex virus infection in neonates. J Infect Dis 1988; 158:109-16.
104. 104. Whitley R, Arvin A, Prober C, et al. A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. N Engl J Med 1991; 324:444-9.
105. 105. Whitley RJ, Nahmias AJ, Visintine AM, Fleming CL, Alford CA. The natural history of herpes simplex virus infection of mother and newborn. Pediatrics 1980; 66:489-94.
106. 106. Hensleigh PA. Undocumented history of maternal genital herpes followed by neonatal herpes meningitis. J Perinatol 1994; 14:216-8.
107. 107. Whitley R, Arvin A, Prober C, et al. Predictors of morbidity in neonates with herpes simplex virus infections. N Engl J Med 1991; 324:450-4.
108. 108. American College of Obstetricians and Gynecologists. Perinatal herpes simplex virus infections. Washington, DC: American College of Obstetricians and Gynecologists, 1988; ACOG technical bulletin 122.
109. 109. Yeager AS, Arvin AM. Reasons for the absence of a hislory of recurrent genital infections in mothers of neonates infected with herpes simplex virus. Pediatrics 1984; 73:188-93.
110. 110. Brown ZA, Benedetti J, Ashley R, et al. Neonatal herpes simplex virus infections in relation to asymptomatic maternal infection at the time of labor. N Engl J Med 1991; 324:1247-52.
111. 111. Randolph AG, Washington AE, Prober CG. Caesarean delivery for women presenting with genital herpes lesions: efficacy, risks, and costs. JAMA 1993; 270:77-82.
112. 112. Scott LL, Sanchez PJ, Jackson GL, Zeray F, Wendel GD. Acyclovir suppression to prevent cesarean delivery after first episode genital herpes. Obstet Gynecol 1996; 87:69-73.
113. 113. Brockelhurst P, Kinghorn G, Carney O, et al. A randomized placebo controlled trial of suppressive acyclovir in late pregnancy in women with recurrent genital herpes infection. Br J Obstet Gynaecol 1998; 105: 275-80.
114. 114. Oh JO. Ocular infections of herpes simplex virus type II in adults. In: Darrell RW, ed. Viral diseases of the eye. Philadelphia: Lea & Febiger, 1985: 59-62.
115. 115. Pavan-Langston D. Major ocular viral infections. In: Galasso GJ, Whitley RJ, Merigan TC, eds. Antiviral agents and viral diseases of man. 3d ed. New York: Raven Press, 1990:183-234.
116. 116. Hill JM, Rayfield MA, Haruta Y. Strain specificity of spontaneous and adrenergically induced HSV-1 ocular reactivation in latently infected rabbits. Curr Eye Res 1987; 6:91-7.
117. 117. Gerdes JC, Smith DS. Recurrence phenotypes and establishment of latency following rabbit keratitis produced by multiple herpes simplex virus strains. J Gen Virol 1983; 64:2441-54.
118. 118. Yoshikawa T, Hill JM, Stanberry LR, Bourne N, Kurawadwala JF, Krause PR. The characteristic site-specific reactivation phenotypes of HSV-1 and HSV-2 depend upon the latency-associated transcript region. J Exp Med 1996; 184:659-64.
119. 119. Oh JO, Moschini GB, Okumoto M, Stevens T. Ocular pathogenicity of types 1 and 2 Herpesvirus hominis in rabbits. Infect Immun 1972; 5:412-3.
120. 120. Wander AH, Centifanto YM, Kaufman HE. Strain specificity of clinical isolates of herpes simplex virus. Arch Ophthalmol 1980; 98:1458-61.
121. 121. Hollenberg MJ, Wilkie JS, Hudson JB, Lewis BJ. Lesions produced by human herpesviruses 1 and 2. Arch Ophthalmol 1976; 94:127-34.
122. 122. Rinne JR, Abghari SZ, Stulting RD. The severity of herpes simplex viral keratitis in mice does not reflect the severity of disease in humans. Invest Ophthalmol Vis Sci 1992; 33:268-72.
123. 123. Notkins AL, Bankowski RA, Baron S, et al. Workshop on the treatment and prevention of herpes simplex virus infections. J Infect Dis 1973; 127: 117-9.
124. 124. Liesegang TJ, Melton LJ, Daly PJ, Ilstrup DM. Epidemiology of ocular herpes: incidence in Rochester, Minn, 1950 through 1982. Arch Ophthalmol 1989; 107:1155-9.
125. 125. Gundersen T. Herpes corneae with special reference to its treatment with strong solution of iodine. Arch Ophthalmol 1936; 15:225-49.
126. 126. Darougar S, Wishart MS, Viswalingam ND. Epidemiologic and clinical features of primary herpes simplex virus ocular infection. Br J Ophthalmol 1985; 69:2-6.
127. 127. Liesegang TJ. Epidemiology of ocular herpes simplex: natural history in Rochester, Minn, 1950 through 1982. Arch Ophthalmol 1989; 107: 1160-5.
128. 128. Wilhelmus KR, Coster DJ, Donovan HC, Falcon MG, Jones BR. Prognostic indicators of herpetic keratitis: analysis of a five-year observation period after corneal ulceration. Arch Ophthalmol 1981; 99:1578-82.
129. 129. Shuster JJ, Kaufman HE, Nesburn AB. Statistical analysis of the rate of recurrence of herpesvirus ocular epithelial disease. Am J Ophthalmol 1981; 91:328-31.
130. 130. Spruance SL. Herpes simplex labialis. In: Sacks SL, Straus SE, Whitley RJ, Griffiths PD, eds. Clinical management of herpes viruses. Amsterdam: IOS Press, 1995:3-42.
131. 131. Overall JC Jr, Spruance SL, Green JA. Viral-induced leukocyte interferon in vesicle fluid from lesions of recurrent herpes labialis. J Infect Dis 1981; 143:543-7.
132. 132. Spruance SL. Pathogenesis of herpes simplex labialis: excretion of virus in the oral cavity. J Clin Microbiol 1984; 19:675-9.
133. 133. Norn MS. Dendritic (herpetic) keratitis. I. Incidence - seasonal variations recurrence rate - visual impairment - therapy. Acta Ophthalmol (Copenh) 1970; 48:91-107.
134. 134. Thygeson P, Kimura SJ, Hogan MJ. Observations on herpetic keratitis and keratoconjunctivitis. Arch Ophthalmol 1956; 56:375-88.
135. 135. Egerer I, Stary A. Erosive-ulcerative herpes simplex blepharitis. Arch Ophthalmol 1980; 98:1760-3.
136. 136. Tullo AB, Shimeld C, Blyth WA. Hill TJ, Easty DL. Spread of virus and distribution of latent infection following ocular herpes simplex in the non-immune and immune mouse. J Gen Virol 1982; 63:95-101.
137. 137. Whitley RJ, Soong S-J, Dolin R, et al. Adenine arabinoside therapy of biopsy-proved herpes simplex encephalitis. N Engl J Med 1977; 297: 289-94.
138. 138. Gilbert GL. Herpes simplex encephalitis. Royal Children's Hospital, Melbourne 1983-1990. Melbourne: Royal Children's Hospital, 1991; Royal Children's Hospital Infectious Diseases Bulletin.
139. 139. Sköldenberg B, Alestig K, Burman L, et al. Acyclovir versus vidarabine in herpes simplex encephalitis: randomised multicentre study in consecutive Swedish patients. Lancet 1984; 2:707-11.
140. 140. Whitley RJ, Soong S-J, Linneman C, et al. Herpes simplex encephalitis: clinical assessment. JAMA 1982; 247:317-20.
141. 141. Whitley RJ, Cobbs CG, Alford CA Jr, et al. Diseases that mimic herpes simplex encephalitis: diagnosis, presentation and outcome. NIAD Collaborative Antiviral Study Group. JAMA 1989; 262:234-9.
142. 142. Kapur N, Barker S, Burrows EH, et al. Herpes simplex encephalitis: long term magnetic resonance imaging and neuropsychological profile. J Neurol Neurosurg Psychiatry 1994; 57:1334-42.
143. 143. Aurelius E, Johansson B, Skoldenberg B, Staland A, Forsgren M. Rapid diagnosis of herpes simplex virus encephalitis by nested polymerase chain reaction assay of cerebrospinal fluid. Lancet 1991; 337:189-92.
144. 144. Corey L, Wald A. Genital herpes. In: Holmes KK, Sparling PF, Mardh P-A, et al., eds. Sexually transmitted diseases. New York: McGraw-Hill, 1999:285-312.
145. 145. Furata Y, Fukuda S, Chida E, et al. Reactivation of herpes simplex virus type 1 in patients with Bell's palsy. J Med Virol 1998; 54:162-6.
146. 146. Stanberry LR, Bernstein DI, Burke RL, Pachl C, Myers MG. Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes. J Infect Dis 1987; 155:914-20.
147. 147. Bastuji-Garin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis: Stevens-Johnson syndrome and erythema multiforme. Arch Dermatol 1993; 129:92-6.
148. 148. Chan HL, Stern RS, Arndt KA, et al. The incidence of erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol 1990; 126:43-7.
149. 149. Strom BL, Carson JL, Halpern AC, et al. A population-based study of Stevens-Johnson syndrome. Arch Dermatol 1991; 127:831-8.
150. 150. Rook WE. Disorders of blood vessels. In: Champion RH, Burton JL, Ebling FJG, eds. Textbook on dermatology. 5th ed. Vol 3. London: Blackwell, 1992:1834-8.
151. 151. Brice SL, Krzemien D, Weston WL, Huff JC. Detection of herpes simplex virus DNA in cutaneous lesions of erythema multiforme. J Invest Dermatol 1989; 93:183-7.
152. 152. Aslanadenh J, Helm KF, Espy MJ, Muller SA, Smith TF. Detection of HSV-specific DNA in biopsy tissue of patients with erythema multiforme by polymerase chain reaction. Br J Dermatol 1993; 128:542-5.
153. 153. Schofield JK, Tatnall FM, Leigh IM. Recurrent erythema multiforme: clinical features and treatment in a large series of patients. Br J Dermatol 1993; 128:542-5.
154. 154. Brice SL, Leahy MA, Ong L, et al. Examination of non-involved skin, previously involved skin, and peripheral blood for herpes simplex virus DNA in patients with recurrent herpes-associated erythema multiforme. J Cutan Pathol 1994; 21:408-12.
155. 155. Khalil I, Lepage V, Douay C, et al. HLA-DBQB1*0301 allele is involved in susceptibility to erythema multiforme. J Invest Dermatol 1991; 97: 697-700.
156. 156. Higgins CR, Schofield JK, Tatnall FM, Leigh IM. Natural history, management and complications of herpes labialis. J Med Virol 1993;(Suppl 1):22-6.
157. 157. Bork K, Bruninger W. Increasing incidence of eczema herpeticum: analysis of seventy-five cases. J Am Acad Dermatol 1988; 19:1024-9.
158. 158. Szucs TD, Berger K, Wielinski C. The economic burden of genital herpes in the United States: an analysis using two different costing approaches [abstract O156]. In: Abstracts of the International Congress of Sexually Transmitted Diseases (Seville, Spain), 1997:87.
159. 159. Randolph AG, Hartshorn RM, Washington AE. Acyclovir prophylaxis in late pregnancy to prevent neonatal herpes: a cost-effectiveness analysis. Obstet Gynecol 1996; 88:603-10.
160. 160. Stanberry LR. Herpes immunization - on the threshold. J Eur Acad Dermatol Venereol 1996; 7:120-8.
161. 161. Spector FC, Kern ER, Palmer J, et al. Evaluation of a live attenuated recombinant virus RAV 9395 as a herpes simplex virus type 2 vaccine in guinea pigs. J Infect Dis 1998; 177:1143-54.
162. 162. Hickling JK, Chrisholm SE, Duncan IA, et al. Immunogenicity of a disabled infectious single cycle HSV-2 vaccine in phase I clinical trials in HSV-2 seropositive and seronegative volunteers [abstract 22.008]. In: Abstracts of the 8th International Congress on Infectious Diseases (Boston). Belle Mead, NJ: Excerpta Medica, 1998:89.
163. 163. Roberts JSC, Uttridge JA, Hickling JK, et al. Safety, tolerability and viral containment of a disabled infectious single cycle HSV-2 vaccine evaluated in phase I clinical trials in HSV-2 seropositive and seronegative volunteers [abstract 22.009]. In: Abstracts of the 8th International Congress on Infectious Diseases (Boston). Belle Mead, NJ: Excerpta Medica, 1998: 89.
164. 164. Corey L, Langenberg AG, Ashley R, et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized control trials. Chiron HSV Vaccine Study Group. JAMA 1999; 282:331-40.
165. 165. Leroux-Roels G, Moreau E, Desombre I, et al. Persistence of humoral and cellular immune response and booster effect following vaccination with herpes simplex (gD2) candidate vaccine with MPL [abstract H57]. In: Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (Orlando, FL). Washington, DC: American Society for Microbiology, 1994:205.
166. 166. Bernstein DI, Tepe ER, Mester JC, Arnold RL, Stanberry LR, Higgins T. Effects of DNA immunization formulated with bupivacaine in murinc and guinea pig models of genital herpes simplex virus infection. Vaccine 1999; 17:1681-9.
167. 167. Da Costa XJ, Jones CA, Knipe DM. Immunization against genital herpes with a vaccine virus that has defects in productive and latent infection. Proc Natl Acad Sci USA 1999; 96:6994-8.
168. 168. Skinner GR, Fink C, Melling J, et al. Report of twelve years experience in open study of Skinner herpes simplex vaccine towards prevention of herpes genitalis. Med Microbiol Immunol (Berl) 1992; 180:305-20.
169. 169. Mertz GJ, Ashley R, Burke RL, et al. Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection. J Infect Dis 1990; 161:653-60.
170. 170. Burke RL. Contemporary approaches to vaccination against herpes simplex virus. CurrTop Microbiol Immunol 1992; 179:137-58.
171. 171. Stanberry LR. Genital and perinatal herpes simplex virus infections: prophylactic vaccines. In: Stanberry LR, Bernstein DI, eds. Sexually transmitted diseases: vaccines, prevention and control. London: Academic Press, 2000:187-216.
172. 172. Krause PR, Straus SE. Herpesvirus vaccines. Development, controversies, and applications. Infect Dis Clin North Am 1999; 13:61-81.
173. 173. Meignier B, Longnecker R, Roizman R. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents. J Infect Dis 1988; 158:602-14.
174. 174. Morrison LA, Knipe DM. Immunization with replication-defective mutants of herpes simplex virus type 1: sites of immune intervention in pathogenesis of challenge virus infection. J Virol 1994; 68:689-96.
175. 175. Farrel HE, McLean CS, Harley C, et al. Vaccine potential of a herpes simplex virus type 1 mutant with an essential glycoprotein deleted. J Virol 1994; 68:927-32.
176. 176. Da Costa XJ, Bourne N, Knipe DM. Construction and characterization of a replication-defective herpes simplex virus 2 ICP8 mutant strain and its use in immunization studies in a guinea pig model of genital disease. Virology 1997; 232:1-12.
177. 177. Boursnell ME, Entwisle C, Blakeley D, et al. A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease. J Infect Dis 1997; 175:16-25.
178. 178. Gallichan WS, Johnson DC, Graham FL, Rosenthal KL. Mucosal immunity and protection after intranasal immunization with recombinant adenovirus expressing herpes simplex virus glycoprotein B. J Infect Dis 1993; 168:622-9.
179. 179. Heineman TC, Connelly BL, Bourne N, Stanberry LR, Cohen JI. Immunization with recombinant varicella-zoster virus expressing herpes simplex virus type 2 glycoprotein D reduces the severity of genital herpes in guinea pigs. J Virol 1995; 69:8109-13.
180. 180. Chabalgoity JA, Khan CM, Nash AA, Hormaeche CE. A Salmonella typhimurium htrA live vaccine expressing multiple copies of a peptide comprising amino acids 8-23 of herpes simplex virus glycoprotein D as a genetic fusion to tetanus toxin fragment C protects mice from herpes simplex virus infection. Mol Microbiol 1996; 19:791-801.
181. 181. Stanberry LR. Herpes simplex virus vaccines. Seminars in Pediatric Infectious Diseases 1991; 2:178-85.
182. 182. Stanberry LR. Subunit viral vaccines: therapeutic and prophylactic uses. In: Aurelian L, ed. Herpesviruses, the immune system and AIDS. Boston: Kluwer Academic Publishers, 1991:309-41.
183. 183. Straus SE, Corey L, Burke RL, et al. Placebo-controlled trial of vaccination with glycoprotein D of herpes simplex virus type 2 immunothcrapy of genital herpes. Lancet 1994; 343:1460-3.
184. 184. Langenberg AG, Burke RL, Adair SF, et al. A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity. Ann Intern Med 1995; 122:889-98.
185. 185. Straus SE, Wald A, Kost RG, et al. Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled trial. J Infect Dis 1997; 176: 1129-34.
186. 186. Bourne N, Milligan GN, Schleiss MR, Bernstein DI, Stanberry LR. DNA immunization confers protective immunity on mice challenged intravaginally with herpes simplex virus type 2. Vaccine 1996; 14:1230-4.
187. 187. Bourne N, Stanberry LR, Bernstein DI, Lew D. DNA immunization against experimental genital herpes simplex virus infection. J Infect Dis 1996; 173:800-7.
188. 188. McClements WL, Armstrong ME, Keys RD, Liu MA. Immunization with DNA vaccines encoding glycoprotein D or glycoprotein B, alone or in combination induces protective immunity in animal models of herpes simplex virus disease. Proc Natl Acad Sci USA 1996; 93:11414-20.
189. 189. Rouse BT, Nair S, Rouse RJ, et al. DNA vaccines and immunity to herpes simplex virus. Curr Top Microbiol Immunol 1998; 226:69-78.
190. 190. Patriarca PA, Weber JA, Parker RA, et al. Efficacy of influenza in nursing homes. Reduction in illness and complications during an influenza A (H3N2) epidemic. JAMA 1985; 253:1136-9.
191. 191. Long SS, Welkon CJ, Clark JL. Widespread silent transmission of pertussis in families: antibody correlates of infection and symptomatology. J Infect Dis 1990; 161:480-6.
192. 192. Long SS, Clarkson JA. The recurrence of whooping cough: possible implications for assessment of vaccine efficacy. Lancet 1982; 1:666-8.
193. 193. Fine PEM, Clarkson JA. Reflections on the efficacy of pertussis vaccines. Rev Infect Dis 1987; 9:866-9.
194. 194. Clements ML, Betts RF, Murphy BR. Advantage of live attenuated cold-adapted influenza A wild type virus infection. Lancet 1984; 1:705-7.
195. 2 cold-adapted and avian-human influenza A reassortment viruses and inactivated virus vaccines in adults. J Infect Dis 1988; 158:1209-13.
196. 196. Clements ML, Betts RF, Tierney EL, Murphy BR. Resistance of adults to challenge with influenza A wild-type virus after receiving live or inactivated virus vaccine. J Clin Microbiol 1986; 23:73-9.
197. 2, cold-adapted vaccine recombinant in which vaccine associated illness occurred in normal volunteers. J Med Virol 1988; 26:175-81.
198. 198. Keadle TL, Laycock KA, Miller JK, et al. Efficacy of a recombinant glycoprotein D subunit vaccine on the development of primary and recurrent ocular infection with herpes simplex virus type 1 in mice. J Infect Dis 1997; 176:331-8.